AI Article Synopsis

  • Simultaneous liver and kidney transplantation (SLKT) can be performed on patients with high donor-specific HLA antibodies or O recipients with high A2 anti-body titers; this case is the first of its kind involving a highly sensitized O recipient receiving organs from an A2 donor.
  • A 59-year-old woman suffering from chronic kidney disease and liver failure underwent the SLKT after pre-transplant testing indicated a negative crossmatch and no HLA antibodies; however, a blood transfusion and memory response from past pregnancies led to a significant increase in antibody reactivity just before the procedure.
  • The transplantation occurred successfully, with the liver transplanted first, followed by the kidney; the recipient showed no signs of rejection four months post-operation

Article Abstract

Simultaneous liver and kidney transplantation (SLKT) is possible for patients with high donor-specific HLA antibodies or with A2 donors to O recipients with high A2 titers. We report the first case of SLKT in a highly sensitized O recipient with organs from an A2 donor. The recipient is a 59-year-old woman with chronic kidney disease and liver failure due to autoimmune hepatitis and drug-induced liver injury. Immune work-up 8 days pre-transplant demonstrated a negative crossmatch and no HLA antibody (calculated panel reactive antibodies = 0%). Anti-A2 IgG levels were 512. The donor was a deceased 24-year-old man. One day before transplantation, serum from the recipient showed a significant increase in antibody reactivity (calculated panel reactive antibodies = 100%) attributable to blood product transfusion and memory response from previous pregnancies. Consequently, a crossmatch was positive for T and B cells with two newly detected HLA antibodies against the donor's antigens. On the day of surgery, the liver was transplanted first. Six hours and 37 minutes later, a repeat flow crossmatch was negative; donor-specific antibodies (DSAs) fell below the positive threshold, and anti-A2 IgG titer fell to 256. Thus, the kidney was transplanted after basiliximab induction therapy. Seven days post-transplant, non-donor-specific HLA antibodies were present but DSAs remain negative. The patient was discharged on postoperative day 57 with no signs of rejection at 4 months. This case illustrates a rapid and prolonged reduction in antibody titers (HLA and ABO) after SLKT. SLKT is feasible in patients with both DSA and high anti-A2 titer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2024.05.017DOI Listing

Publication Analysis

Top Keywords

hla antibodies
12
simultaneous liver
8
liver kidney
8
kidney transplantation
8
calculated panel
8
panel reactive
8
reactive antibodies
8
anti-a2 igg
8
antibodies dsas
8
hla
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!